Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Aducanumab
1:38
ALZ-NET: examining novel approved treatments in the real-world
Rebecca Edelmayer
• 18 May 2023
3:49
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Philip Tipton
• 27 Apr 2023
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway
• 19 Apr 2023
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway
• 19 Apr 2023
4:51
Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310
Johanne Kaplan
• 30 Mar 2023
1:35
Lecanemab vs aducanumab
Alvaro Pascual-Leone
• 9 Jan 2023
5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain
• 6 Dec 2022
5:40
Future direction for anti-amyloid immunotherapies
Nicolas Villain
• 6 Dec 2022
1:13
Is amyloid load a valid surrogate endpoint for AD clinical trials?
Nicolas Villain
• 6 Dec 2022
5:36
Lowering blood pressure as a treatment for VCID
Atticus Hainsworth
• 16 Aug 2022
3:17
Impact of Alzheimer’s disease treatments on apathy
Krista Lanctôt
• 11 Aug 2022
6:38
Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)
Stephen Salloway
• 19 Aug 2022
2:24
Is amyloid lowering still a valid approach in Alzheimer’s disease?
Johannes Streffer
• 2 Aug 2022
1:14
Potential of anti-amyloid drugs for treating Alzheimer’s disease
Oscar López
• 4 Apr 2022
4:52
Important developments in dementia: biomarkers & clinical trials
Philip Tipton
• 3 Apr 2022
4:01
Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab
Lars Lannfelt
• 16 Mar 2022
1
2
Next